Taysha Gene Therapies Inc

General ticker "TSHA" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $570.7M

Taysha Gene Therapies Inc follows the US Stock Market performance with the rate: 14.2%.

Estimated limits based on current volatility of 2.3%: low 1.81$, high 1.89$

Factors to consider:

  • Price in estimated range
  • Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [1.35$, 3.37$]
  • 2024-12-30 to 2025-12-30 estimated range: [1.16$, 2.93$]

Financial Metrics affecting the TSHA estimates:

  • Negative: Non-GAAP EPS, $ of -0.44 <= 0.10
  • Negative: Operating profit margin, % of -82.42 <= 1.03
  • Negative: Operating cash flow per share per price, % of -27.18 <= 2.35
  • Negative: negative Net income
  • Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
  • Negative: Industry earnings per price (median), % of -26.04 <= 1.31

Similar symbols

Short-term TSHA quotes

Long-term TSHA plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $0.00MM $2.50MM $15.45MM
Operating Expenses $173.27MM $164.95MM $87.89MM
Operating Income $-173.27MM $-162.45MM $-72.44MM
Non-Operating Income $-1.26MM $-3.57MM $-39.13MM
Interest Expense $1.43MM $3.80MM $5.00MM
R&D Expense $131.94MM $91.17MM $56.78MM
Income(Loss) $-174.52MM $-166.01MM $-111.57MM
Profit(Loss) $-174.52MM $-166.01MM $-111.57MM
Stockholders Equity $95.38MM $0.95MM $74.94MM
Assets $213.96MM $126.28MM $172.73MM
Operating Cash Flow $-117.04MM $-88.39MM $-73.02MM
Capital expenditure $21.55MM $24.87MM $7.37MM
Investing Cash Flow $-21.55MM $-24.93MM $-7.35MM
Financing Cash Flow $39.08MM $52.10MM $136.39MM
Earnings Per Share* $-4.66 $-3.86 $-0.96

* EPS are Split Adjusted, recent splits may be reflected with a delay.